2026 prior auth tightening for obesity‑related GLP‑1 combos after CVS Caremark’s updated documentation standards and CMS’s new utilization‑management reporting rule
Beginning January 1, 2026, major pharmacy benefit managers are rolling out tighter prior authorization (PA) criteria for GLP‑1 receptor agonist combinations used in obesity management. This comes right after CVS Caremark published updated documentation standards in March and as new CMS utilization‑management (UM) reporting requirements kick in for the same plan year. So yes, the administrative screws are turning.
Data: new UM reporting and PBM compliance
The CMS 2026 final rule (CMS‑4205‑F) now requires Medicare Part D and ACA marketplace plans to report UM metrics every quarter, denial rates, turnaround times, the works. CMS said it wants to spot patterns of “inappropriate access restriction,” and GLP‑1 combos prescribed for obesity (not diabetes) are front and center in that analysis. There’s real money involved, and regulators want to see where it’s going.
CVS Caremark, which manages pharmacy benefits for roughly 105 million members as of early 2026, rolled out revised PA templates for GLP‑1 combinations paired with agents like bupropion or metformin. The forms now ask for:
- Proof of diagnosis (BMI ≥30, or ≥27 with a related condition) using ICD‑10‑CM codes Z68.30-Z68.39.
- Baseline and 12‑week weight data.
- Evidence of trial and failure of at least one lower‑cost anti‑obesity drug (like generic phentermine/topiramate) unless contraindicated.
It’s not a box‑checking exercise anymore, plans actually audit this stuff now.
Drugs affected in 2026 formularies
| Drug (Brand / Generic) | Manufacturer | Indication | Typical Tier (2026) |
|---|---|---|---|
| Wegovy (semaglutide) | Novo Nordisk | Weight management | Tier 3 preferred specialty |
| Zepbound (tirzepatide) | Eli Lilly | Chronic weight management | Tier 3‑4 specialty with PA |
| Experimental GLP‑1 + bupropion combo (late‑phase pipeline) | Multiple manufacturers | Obesity, adjunct therapy | Non‑formulary pending FDA approval |
Most 2026 plan materials split obesity and diabetes indications into separate review tracks. Even when it’s the same compound, Ozempic versus Wegovy, for instance, the coding drives the coverage. Pharmacists now have to double‑check indication codes before claims go in, and benefits managers are patching their PA portals to capture all the new data points from CVS Caremark’s checklist and CMS’s quarterly reports.
Impact on patients and clinicians
Patients starting a GLP‑1‑based weight‑loss therapy in 2026 are seeing longer waits, five to seven business days isn’t unusual, compared to the 72‑hour turnaround norm for urgent diabetes starts. Clinicians need recent documentation on BMI or labs when renewing. The idea is to cut down on off‑label obesity prescribing while giving CMS a data trail that shows how these drugs affect overall pharmacy spend. And that spend isn’t small, KFF tracking shows an 8.9% rise year‑over‑year in early 2026.
Honestly, this level of scrutiny has been coming for a while. The big plans are just catching up to their own cost spikes.
Disclaimer: This summary is for informational and policy reference purposes only. It shouldn’t replace payer‑specific requirements or professional clinical judgment.